Skip to main content

Valvular Heart Disease

0
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
Abbott Mechanical Heart ValveN/A1 trial
EPICN/A1 trial
Active Trials
NCT05330468Completed200Est. Oct 2024
NCT00329667Completed761Est. Sep 2008
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
HBCR hands-offN/A1 trial
Active Trials
NCT06077201Recruiting375Est. Oct 2026
Medtronic
MedtronicNJ - Phillipsburg
1 program
ICD implantationN/A1 trial
Active Trials
NCT03590730Terminated12Est. Jul 2021
Protembis
ProtembisGermany - Aachen
1 program
cerebral embolic protection during TAVRN/A1 trial
Active Trials
NCT04618718Completed64Est. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Colorado TherapeuticsHBCR hands-off
AbbottAbbott Mechanical Heart Valve
Protembiscerebral embolic protection during TAVR
MedtronicICD implantation
AbbottEPIC

Clinical Trials (5)

Total enrollment: 1,412 patients across 5 trials

NCT06077201Colorado TherapeuticsHBCR hands-off

Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions

Start: Dec 2023Est. completion: Oct 2026375 patients
N/ARecruiting
NCT05330468AbbottAbbott Mechanical Heart Valve

Regent China Post-Market Clinical Follow-up Study

Start: Mar 2022Est. completion: Oct 2024200 patients
N/ACompleted
NCT04618718Protembiscerebral embolic protection during TAVR

The PROTEMBO C Trial

Start: Jul 2020Est. completion: Nov 202264 patients
N/ACompleted
NCT03590730MedtronicICD implantation

Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy

Start: Nov 2017Est. completion: Jul 202112 patients
N/ATerminated
NCT00329667AbbottEPIC

Observational Study of Prosthetic Tissue Aortic and Mitral Heart Valve

Start: Jan 2003Est. completion: Sep 2008761 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,412 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.